Clinical Trial Update: Phase I Study to Determine the Optimal Human Challenge Dose for a Norovirus GII.4 Challenge Stock (CIN-1) [Phase 1]

View source ↗

Summary

Phase I study to determine the optimal human challenge dose for a Norovirus GII.4 challenge stock has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Norovirus Gastroenteritis

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Gastroenteritis Norovirus | Phase 1 | Status: WITHDRAWN